Compared impact of diabetes on the risk of heart failure from acute myocardial infarction to chronic coronary artery disease.


Journal

Diabetes & metabolism
ISSN: 1878-1780
Titre abrégé: Diabetes Metab
Pays: France
ID NLM: 9607599

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 30 04 2021
revised: 03 06 2021
accepted: 04 06 2021
pubmed: 6 7 2021
medline: 23 3 2022
entrez: 5 7 2021
Statut: ppublish

Résumé

We attempted to describe the risk of heart failure (HF) occurrence according to diabetes mellitus (DM) status in patients with coronary artery disease (CAD) over time, from acute myocardial infarction (MI) to the chronic stable phase. For the acute and subacute MI phases, we analysed the FAST-MI cohort restricted to patients without history of HF (n = 12,473). The analysis on 1-year outcomes after MI was further restricted to patients who were discharged alive and without history of HF and/or HF symptoms during the index hospitalisation for MI (n = 9181). To analyse the chronic phase, we analysed the CORONOR cohort restricted to patients without history of HF (n = 3871). The primary endpoint was HF occurrence according to DM status. We also analysed the composite of all-cause death or HF. Killip-Kimball class ≥II during the index MI hospitalisation was more frequent in DM patients compared to non-DM patients (29% vs. 15.3%, adjusted OR = 1.60). At one year after MI, hospitalisation for HF was more frequent in DM patients (3.3% vs. 1.2%, adjusted HR = 1.73). At the chronic phase (5-year outcomes), hospitalisation for HF was more frequent in DM patients (8.5% vs. 4.3%, adjusted HR = 1.70). Results focusing on the composite endpoint (all-cause death or HF) were consistent. DM was associated with a very constant near 2-fold increase in the risk of HF whatever the presentation of CAD. Avoiding the risk of HF occurrence in CAD patients with DM is critical in daily practice and should be a constant life-long endeavour.

Identifiants

pubmed: 34224895
pii: S1262-3636(21)00048-3
doi: 10.1016/j.diabet.2021.101265
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

101265

Informations de copyright

Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Auteurs

Gilles Lemesle (G)

Heart and Lung Institute, University hospital of Lille, F-59000 Lille, France. Univ. Lille, F-59000, France. Institut Pasteur of Lille, Inserm U1011, F-59000 Lille, France. FACT (French Alliance for Cardiovascular Trials), F-75000 Paris, France. Electronic address: gilles_lemesle@yahoo.fr.

Etienne Puymirat (E)

Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, University of Paris, and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Laurent Bonello (L)

Aix-Marseille Univ, Intensive care unit, Department of Cardiology, Assistance Publique-Hôpitaux de Marseille, Hôpital Nord, Marseille, France, Mediterranean Association for Research and Studies in Cardiology (MARS Cardio), Marseille, France, Centre for CardioVascular and Nutrition research (C2VN), INSERM 1263, INRA 1260, Marseille, France.

Tabassome Simon (T)

Department of Pharmacology and URCEST, Hôpital St Antoine, University of Paris Sorbonne, and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Philippe-Gabriel Steg (PG)

Department of Cardiology, Hôpital Bichat, AP-HP, University of Paris, and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Jean Ferrières (J)

Department of Cardiology, Rangueil hospital, 31400 Toulouse, France.

François Schiele (F)

Department of Cardiology, University Hospital Jean-Minjoz, 25000 Besançon, France.

Laurent Fauchier (L)

Department of Cardiology, CHU de Trousseau, University François-Rabelais, 37170 Chambray-lès-Tours, France.

Patrick Henry (P)

Cardiology Department, APHP, Lariboisière Hospital, Paris, France. University of Paris, Paris, France.

Guillaume Schurtz (G)

Heart and Lung Institute, University hospital of Lille, F-59000 Lille, France.

Sandro Ninni (S)

Heart and Lung Institute, University hospital of Lille, F-59000 Lille, France. Univ. Lille, F-59000, France. Institut Pasteur of Lille, Inserm U1011, F-59000 Lille, France. FACT (French Alliance for Cardiovascular Trials), F-75000 Paris, France.

Nicolas Lamblin (N)

Heart and Lung Institute, University hospital of Lille, F-59000 Lille, France. Univ. Lille, F-59000, France. Institut Pasteur of Lille, Inserm U1011, F-59000 Lille, France. FACT (French Alliance for Cardiovascular Trials), F-75000 Paris, France.

Christophe Bauters (C)

Heart and Lung Institute, University hospital of Lille, F-59000 Lille, France. Univ. Lille, F-59000, France. Institut Pasteur of Lille, Inserm U1011, F-59000 Lille, France. FACT (French Alliance for Cardiovascular Trials), F-75000 Paris, France.

Nicolas Danchin (N)

Department of Cardiology, Hôpital Européen Georges Pompidou, AP-HP, University of Paris, and FACT (French Alliance for Cardiovascular Trials), Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH